CIK 0001625297 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | |
|---|---|---|
| Revenue (USD) | 1.2 B | 901.0 M |
| Net income (USD) | 210.0 M | |
| Diluted EPS (USD/shares) | 1.64 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-15 | 8-K | FORM 8-K items 5.07 | 2026-10-15 |
| 2026-10-06 | 425 | 425 | |
| 2026-10-06 | 8-K | FORM 8-K items 8.01 | 2026-10-06 |
| 2026-09-30 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-17 | 425 | 425 | |
| 2026-09-17 | 8-K | FORM 8-K items 7.01,8.01,9.01 | 2026-09-16 |
| 2026-09-15 | 8-K | 8-K items 1.02,9.01 | 2026-09-09 |
| 2026-09-11 | EFFECT | EFFECT items ,, | |
| 2026-09-11 | 424B3 | 424B3 | |
| 2026-09-09 | S-4/A | S-4/A | |
| 2026-08-28 | S-4 | S-4 | |
| 2026-08-27 | 4 | FORM 4 | 2026-08-27 |
| 2026-08-13 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-05 | 4 | FORM 4 | 2026-08-05 |
| 2026-08-04 | 425 | 425 | |
| 2026-08-03 | 425 | 425 | |
| 2026-08-03 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-03 | 425 | 425 | |
| 2026-08-03 | 8-K | 8-K items 7.01,9.01 | 2026-08-03 |
| 2026-08-03 | 425 | 425 | |
| 2026-08-03 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-03 |
| 2026-08-03 | 425 | 425 | |
| 2026-08-03 | 8-K | 8-K items 1.01,7.01,9.01 | 2026-08-01 |
| 2026-07-13 | 4 | FORM 4 | 2026-07-10 |
| 2026-07-10 | 144 | 144 |
Forms on file (last 1,000): 6-K 337, 4 39, 8-K 34, SCHEDULE 13D/A 15, 3 13, SCHEDULE 13G/A 11, 144 10, SCHEDULE 13G 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=INDV (0.002 USD), /gw/filings/filings?ticker=INDV&form=8-K, /gw/filings/facts?ticker=INDV&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange